Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $1,200.00 price target on Regeneron Pharma (NASDAQ: REGN)The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments Momentum Movers Trader Talk

Morgan Stanley Reiterates Overweight Rating on Regeneron Pharma (REGN)September 26, 2024 5:56 AM Regeneron slump continues as analysts turn more cautiousSeptember 24, 2024 12:16 PM Leerink Partners Downgrades Regeneron Pharma (REGN) to Market Perform, 'Eylea Franchise Outlook Uncertain'September 24, 2024 6:03 AM Baird Reiterates Neutral Rating on Regeneron Pharma (REGN)September 24, 2024 5:30 AM Goldman Sachs Reiterates Buy Rating on Regeneron Pharma (REGN)September 24, 2024 5:28 AM U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.15%September 23, 2024 4:49 PM RBC Capital on Regeneron (REGN): 'We see potential earlier-than-expected launch of biosimilar product as incrementally negative to REGN's story'September 23, 2024 4:40 PM BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)September 23, 2024 4:00 PM Truist Securities on Regeneron Pharma (REGN): 'view the pressure on stock as an overreaction'September 23, 2024 3:40 PM Regeneron (REGN) Reports Dupixent Recommended for EU Approval by the CHMPSeptember 20, 2024 7:45 AM Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year OldSeptember 20, 2024 7:45 AM Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year oldSeptember 20, 2024 7:45 AM